All In Biotech

NDA 018413 · Chartwell Rx

Furosemide

Furosemide · Oral · Loop Diuretic

Discontinued

Last checked: Nov 20, 2026Latest source record: Aug 7, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

Nov 30, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

345

66 Phase 3, 33 recruiting

FAERS reports

265,537

219,231 serious, 40,876 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2025.

INDICATIONS AND USAGE Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 30, 1983 Original approval
2 products under this application
  • FUROSEMIDE · FUROSEMIDE 40MG · TABLET, ORAL · Discontinued
  • FUROSEMIDE · FUROSEMIDE 20MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.

All 345 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea18,437
  • acute kidney injury16,467
  • fatigue13,248
  • diarrhoea13,195
  • death12,368
  • nausea11,534
  • fall11,003
  • off label use10,842
  • drug ineffective10,424
  • hypotension10,330
  • pneumonia10,172
  • dizziness9,887

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,479
20053,857
20063,623
20073,214
20083,608
20093,997
20104,832
20116,479
20127,274
20137,405
201410,059
201513,254
201616,201
201716,716
201821,192
201923,004
202020,355
202118,734
202216,306
202316,473
202417,411
202516,227
202611,830

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Furosemide* (Furosemide)

2024 spending

$119M

Beneficiaries

5,790,198

23,553,663 claims

Per beneficiary

$21

$0.08 per unit

View as table
YearSpending
2020$147,144,669
2021$140,004,881
2022$139,702,947
2023$144,867,352
2024$118,928,717

Part B: Furosemide (Furosemide) · HCPCS J1940

2024 spending

$30K

Beneficiaries

16,747

27,644 claims

Per beneficiary

$2

2024 ASP limit $0.50 per unit

View as table
YearSpending
2020$50,841
2021$44,701
2022$40,222
2023$37,593
2024$29,817

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,427 on PubMed

Sponsor: Chartwell Rx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.